Creative Biolabs streamlines bispecific antibody development by merging genetic engineering, cell-free expression, and high-throughput screening into a single, comprehensive pipeline.
— During the development of bispecific antibodies, the efficient heterodimerization and the reduction of impurity levels (such as homodimers) have always been a challenge in the industry. Experts from Creative Biolabs stated, “The success of BsAb largely depends on the selection of the manufacturing process. We no longer limit ourselves to a single technology, but provide customized solutions based on the specific application scenarios of our clients.”
Currently, the company’s BsAb manufacturing platform encompasses three major approaches:
Genetic engineering and protein engineering: Focus on developing IgG-like molecules, antibody fragments (such as scFv and Fab), and bispecific fusion proteins. Through advanced humanization modification techniques, the potential immunogenicity is minimized.
Chemical conjugation technology: Utilize highly precise bifunctional cross-linking agents (such as SPDP and EDC) to covalently connect two parent antibodies with different specificities.
Hybrid-hybridoma technology: Although the process is complex, this technology produces antibodies that retain full Fc effector functions (such as ADCC and CDC), offering distinct advantages over antibody fragments in enhancing anti-tumor activity.
Cell-Free Systems: “In Vitro Factories”
For certain proteins that are cytotoxic or difficult to express through conventional mammalian cells (such as CHO cells), Creative Biolabs has specially launched a cell-free bispecific antibody expression platform.
This “in vitro translation” system breaks the limitations of the internal environment of living cells. According to the technical director of Creative Biolabs, “The cell-free system allows us to directly adjust the reaction conditions in an open environment. For example, adding accessory proteins to facilitate the correct folding of challenging ‘knobs-into-holes’ variants. This significantly improves the synthesis efficiency of complex BsAb and avoids the common protein degradation problems in living cells.”
This platform currently supports various systems, including prokaryotic (bacterial extract) and eukaryotic (such as wheat germ and human cell lysate) ones, ensuring that even antibody molecules with complex glycosylation modifications can achieve high-quality expression.
HTP Screening: Speeding Lab-to-Clinic Transition
In the early stages of drug development, speed often determines market competitiveness. Creative Biolabs’ high-throughput antibody expression platform is specifically designed for large-scale candidate drug screening. Through automated operation procedures, the company can compress the research and development cycle to 3-5 weeks.
This high-throughput platform possesses the following core capabilities:
Diverse Formats: It covers full-length IgG, Fab, VHH (single-domain antibodies), and multi-specific antibody formats.
Strict characterization: All products have undergone multi-dimensional validations such as ELISA and SPR (surface plasmon resonance), ensuring that the affinity and stability meet the standards.
Scale-up potential: The optimal sequences selected can seamlessly connect to the subsequent large-scale production stage, significantly reducing the risk of fluctuations between experiments.
“Bispecific antibodies are not just a simple combination of 1+1=2. They are highly complex biological products.” The expert pointed out when discussing industry trends, “By combining high-throughput screening with cell-free expression technology, we are helping our clients address the two major core pain points of ‘low expression levels’ and ‘high mismatch ratios.’ Our goal is to enable every innovative therapy to reach the clinic through a shorter path.”
About
Creative Biolabs delivers world-class antibody development and biomarker services, maintaining a leading edge in the bispecific antibody field to support global biopharma innovation.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/bsab/
Release ID: 89181885
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.